Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06013592
Other study ID # 23HH8298
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 29, 2023
Est. completion date August 2025

Study information

Verified date September 2023
Source Imperial College London
Contact Tony Goldstone, MRCP PhD
Phone +44 20 7594 5989
Email tony.goldstone@imperial.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this interventional study is to measure the blood levels of the gut hormones LEAP2 and acyl ghrelin (AG), appetite and food intake after consuming liquid meals of different caloric sizes, in healthy adults with and without obesity. AG is a stomach-derived homone that increases appetite, and LEAP2 a liver-gut derived hormone that decreases appetite, which interferes the action of AG ant its receptor in the brain called the growth hormone secretagogue receptor (GHSR). Blood levels of AG and LEAP2 change in opposite directions after food intake (AG decreasing, LEAP2 increasing). AG is formed from an inactive version of hormone called desacyl ghrelin (DAG). Previous studies have shown that greater food intake leads to a greater decrease in blood levels of total ghrelin (AG + DAG), but this has not been studied for changes in blood AG or LEAP2 after eating. Blood levels of AG and total ghrelin when fasted and after food intake are lower, while blood levels of LEAP2 are higher, in adults with than those without obesity. The main study questions are: 1. Are there greater increases in blood levels of LEAP2 and greater decreases in blood levels of AG after consuming larger meals (by amount of calories they contain)? 2. Are greater decreases in appetite after connsuming larger meals related to greater increases in blood levels of LEAP2 and greater decreases in blood levels of AG? 3. Are greater decreases in food intake at a buffet lunch after consuming larger meals eaten a few hours previously related to greater increases in blood levels of LEAP2 and greater decreases in blood levels of AG? 4. Do the above findings differ between adults without obesity and with obesity? Healthy adults (without and with obesity) will consume liquid meals containing different amounts of calories (0, 600, 1200, 1800 kcal, of identical total volume) after an overnight fast and have measurements of blood LEAP2 and AG and appetite ratings from 0 to 180 min, and have food intake at a buffet lunch measured at 180 mins.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date August 2025
Est. primary completion date August 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Male or female between the ages of 18 and 60 years; - Without obesity with body mass index (BMI) 18.0-29.9 kg/m2 or with obesity with BMI 30.0-50.0 kg/m2; - Healthy as determined by medical history and vital signs; - Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form; - Participant is able to read, comprehend and record information written in English. Exclusion Criteria: - History of, or current abuse or dependence on alcohol or drugs; - Current smoker or less than 2 years since quitting (cigarette, cigars, e-cigarettes) or use of nicotine replacement therapy; - Significant current or past medical or psychiatric history that, in the opinion of the investigators, contraindicates their participation; - History of type 1 or type 2 diabetes mellitus; - History of ischaemic heart disease, heart failure, cardiac arrhythmia, peripheral vascular, cerebrovascular disease or uncontrolled hypertension; - Current diagnosis of anaemia or iron deficiency; - Body weight instability (change in body weight of more than 5% over the preceding 3 months); - Use of current regular prescription or over-the-counter medications that in the opinion of the Investigators may affect participant safety or outcome measures; - Clinically significant abnormalities in screening blood tests abnormalities which in the opinion of the study physician, is clinically significant e.g. diabetes mellitus, hypothyroidism, renal impairment, abnormal liver function tests [bilirubin, alanine transaminase (ALT), aspartate transaminase (AST), gamma-glutamyl transferase (GGT)] >3x upper limit of normal, other than due to fatty liver disease; Current pregnancy or breast-feeding in female volunteers (the Investigators will recommend using contraception for the duration of the visits to avoid participant drop-out); - Pulse rate <40 or >100 beats per minute OR systolic blood pressure >160 and <100 OR diastolic blood pressure >95 and <50 in the semi-supine position; - Volunteer has participated in a clinical trial and has received an investigational product within the following time period prior to the first experimental visit in the current study: 90 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer); - Exposure to more than 3 new investigational medicinal products within 12 months prior to the scan; - Vegan, gluten or lactose-intolerant (as test meals in the paradigms may include animal products, dairy and wheat products); - Volunteers who have donated, or intend to donate, blood within three months before the screening visit or following study visit completion; - Known history of SARS-CoV-2 infection (Covid-19) in the last 4 weeks; - Ongoing symptoms suggestive of complications from previous SARS-CoV-2 infection ('long Covid-19') such as loss or change in sense of smell or taste, shortness of breath, palpitations, lethargy; - SCOFF questionnaire score >1/5 indicating eating disorders (Luck et al. 2002); - DSM-V criteria for alcohol use disorder (AUD) >2/11 indicating mild AUD (American-Psychiatric-Association 2013); - Participants who have had previous obesity surgery or are on medications for obesity.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
0 kcal liquid
Flavoured water
Dietary Supplement:
600 kcal liquid meal
Fortisip Compact Vanilla
1200 kcal liquid meal
Fortisip Compact Vanilla
1800 kcal liquid meal
Fortisip Compact Vanilla

Locations

Country Name City State
United Kingdom PsychoNeuroEndocrinology Research Group, Division of Psychiatry, Dept. of Brain Sciences, Imperial College London London

Sponsors (1)

Lead Sponsor Collaborator
Imperial College London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Post-prandial plasma concentration acyl ghrelin Incremental area under curve (iAUC 0-180 minutes) 0, 30, 60, 120, 180 minutes
Primary Post-prandial plasma concentration LEAP2 Incremental area under curve (iAUC 0-180 minutes) 0, 30, 60, 120, 180 minutes
Secondary VAS ratings of appetite Incremental area under curve (iAUC 0-180 minutes) 0, 30, 60, 120, 180 minutes
Secondary Ad libitum food intake Total kilocalories adjusted for estimated percentage of resting energy expenditure 180 minutes
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2